Patents Examined by Daniel E. Kolker
  • Patent number: 11447547
    Abstract: The present disclosure relates to methods of re-oxidizing an antigen-binding protein.
    Type: Grant
    Filed: December 13, 2018
    Date of Patent: September 20, 2022
    Assignee: AMGEN INC.
    Inventors: Elaheh Binabaji, Chio Mui Chan, Hadley Krizner, Junfen Ma, Diana Woehle
  • Patent number: 11434291
    Abstract: Provided herein, in one aspect, is a method of preventing or delaying the onset of clinical type 1 diabetes (T1D), comprising: providing a non-diabetic subject who is at risk for T1D; determining that the non-diabetic subject (1) is substantially free of antibodies against zinc transporter 8 (ZnT8), (2) is HLA-DR4+, and/or (3) is not HLA-DR3+; and administering a prophylactically effective amount of an anti-CD3 antibody to the non-diabetic subject.
    Type: Grant
    Filed: May 14, 2020
    Date of Patent: September 6, 2022
    Assignee: Provention Bio, Inc.
    Inventors: Francisco Leon, Kevan C. Herold, Jay S. Skyler
  • Patent number: 11434501
    Abstract: This invention relates to the prevention and treatment of neurodegenerative diseases by administering compositions that increase the activity of a small proline-rich repeat 1 A protein (Sprr1A), or derivative thereof to the brain. Specifically, the compositions may comprise a nucleic acid molecule encoding a Sprr1A protein or a biologically-active portion thereof. The neurodegenerative disease may be Parkinson's Disease, Alzheimer's disease, amyotrophic lateral sclerosis, or traumatic brain injury.
    Type: Grant
    Filed: August 27, 2015
    Date of Patent: September 6, 2022
    Assignee: Board of Trustees of Michigan State University
    Inventors: Jack W. Lipton, Nicholas Kanaan, Timothy Collier
  • Patent number: 11435363
    Abstract: The invention involves, inter alia, the use of markers of systemic inflammation to determine whether or not an individual undergoing treatment with a cardiovascular agent to reduce the risk of a future cardiovascular event will benefit from continued treatment with the cardiovascular agent. Further, this invention describes the use of markers of systemic inflammation to evaluate the efficacy of treatment and to assist physicians in deciding on the course of a treatment in an individual at risk of future cardiovascular events.
    Type: Grant
    Filed: October 19, 2015
    Date of Patent: September 6, 2022
    Assignee: The Brigham and Women's Hospital, Inc.
    Inventor: Paul M. Ridker
  • Patent number: 11419821
    Abstract: This invention relates to coated digestive enzyme preparations and enzyme delivery systems and pharmaceutical compositions comprising the preparations. This invention further relates to methods of preparation and use of the systems, pharmaceutical compositions and preparations to treat persons having ADD, ADHD, autism, cystic fibrosis and other behavioral and neurological disorders.
    Type: Grant
    Filed: August 14, 2018
    Date of Patent: August 23, 2022
    Assignee: CUREMARK, LLC
    Inventors: Joan M. Fallon, Matthew Heil
  • Patent number: 11414482
    Abstract: Antibodies specific for secretogranin III (Scg3) are disclosed. Methods of using the antibodies, antigen-binding fragments thereof, or pharmaceutical compositions comprising the same in the treatment of diseases such as diabetic retinopathy, neovascular age-related macular degeneration, retinopathy of prematurity, and cancer, are also disclosed.
    Type: Grant
    Filed: November 6, 2017
    Date of Patent: August 16, 2022
    Assignee: UNIVERSITY OF MIAMI
    Inventors: Wei Li, Michelle E. Leblanc, Weiwen Wang, Philip J. Rosenfeld
  • Patent number: 11407820
    Abstract: Provided herein are compositions, including pharmaceutical compositions, and methods for modulating, i.e., stimulating or inhibiting, activity of the alternative complement pathway, and methods of identifying factor H-binding proteins.
    Type: Grant
    Filed: June 21, 2018
    Date of Patent: August 9, 2022
    Assignee: The Regents of The University of Colorado
    Inventors: Joshua M. Thurman, V. Michael Holers
  • Patent number: 11401299
    Abstract: The invention relates to the generation of multispecific antibody mixtures include a subset of antibodies isolated from a mixture of two or more monospecific antibodies and one or more bispecific antibodies, wherein all antibodies in the subset have the same common heavy chain. The invention also relates to methods of isolating, purifying, or otherwise producing such a subset of antibodies by using at least one affinity chromatography step. The invention also relates to methods of using such a subset of antibodies in a variety of therapeutic indications.
    Type: Grant
    Filed: July 23, 2018
    Date of Patent: August 2, 2022
    Assignee: NovImmune SA
    Inventors: Nicolas Fischer, Giovanni Magistrelli, Krzysztof Masternak
  • Patent number: 11402392
    Abstract: The present disclosure provides methods to quantify tau phosphorylation at specific amino acid residues to predict time to onset of mild cognitive impairment due to Alzheimer's disease, stage Alzheimer's disease, guide treatment decisions, select subjects for clinical trials, and evaluate the clinical efficacy of certain therapeutic interventions.
    Type: Grant
    Filed: July 6, 2021
    Date of Patent: August 2, 2022
    Assignee: Washington University
    Inventors: Nicolas Barthelemy, Randall Bateman, Eric McDade
  • Patent number: 11376337
    Abstract: Methods of expressing a neuropeptide in a neuron of a subject are described. Methods of altering a behavior in a subject in need thereof are described. Kits are described. Vectors are described.
    Type: Grant
    Filed: November 1, 2018
    Date of Patent: July 5, 2022
    Assignee: California Institute of Technology
    Inventors: David J Anderson, Moriel Zelikowsky
  • Patent number: 11370835
    Abstract: Processes and methods of purifying or separating Single Domain Antigen Binding (SDAB) molecules that include one or more single binding domains (e.g., one or more nanobody molecules), substantially devoid of a complementary antibody domain and an immunoglobulin constant region, using Protein A-based affinity chromatography, are disclosed.
    Type: Grant
    Filed: September 26, 2018
    Date of Patent: June 28, 2022
    Assignee: Ablynx N.V.
    Inventors: Paul R. Brown, Scott Andreas Tobler, Andrew M. Wood, Austin Wayne Boesch
  • Patent number: 11369668
    Abstract: The present disclosure provides an allogeneic whole cell cancer vaccine platform that includes compositions and methods for treating and preventing cancer. Provided herein are compositions containing a therapeutically effective amount of cells from one or more cancer cell lines, some or all of which are modified to (i) inhibit or reduce expression of one or more immunosuppressive factors by the cells, and/or (ii) express or increase expression of one or more immunostimulatory factors by the cells, and/or (iii) express or increase expression of one or more tumor-associated antigens (TAAs), including TAAs that have been mutated, and which comprise cancer cell lines that natively express a heterogeneity of tumor associated antigens and/or neoantigens. Also provided herein are methods of making the vaccine compositions, methods of preparing, and methods of use thereof.
    Type: Grant
    Filed: August 6, 2021
    Date of Patent: June 28, 2022
    Assignee: NEUVOGEN, INC.
    Inventors: Bernadette Ferraro, Todd Merrill Binder, Aleksandr Dolgoter, Matthias Hundt, Kendall M. Mohler, Jian Yan
  • Patent number: 11371039
    Abstract: The present inventors discovered that antibodies having weaker antigen-binding activity at the early endosomal pH in comparison with that at the pH of plasma are capable of binding to multiple antigen molecules with a single antibody molecule, have long half-lives in plasma, and have improved durations of time in which they can bind to antigen.
    Type: Grant
    Filed: September 14, 2020
    Date of Patent: June 28, 2022
    Assignee: Chugai Seiyaku Kabushiki Kaisha
    Inventors: Tomoyuki Igawa, Shinya Ishii, Atsuhiko Maeda, Takashi Nakai
  • Patent number: 11365238
    Abstract: Neutralizing antibodies through recombinant protein expression were identified by mining antibody repertoires by high-throughput second generation sequencing. Sequencing across the majority of light and heavy chain variable regions of chicken immunoglobulins was performed at two immunological time points: a non-immune (naive) state and a post-hyperimmunization state. The mRNA was extracted from unsorted and unselected PBMC populations and identification of antigen-specific antibody sequences leveraged the significant disparity of abundance of an individual B cell clone in non-immune and immunized states. Through bioinformatic analysis, candidate amino acid sequences for variable heavy chain and light chains were identified. Recombinant polypeptides with the binding domains having the identified amino acid sequences for variable heavy chain and light chains were expressed and screened using immunoassays to confirm antigen-specificity.
    Type: Grant
    Filed: December 7, 2016
    Date of Patent: June 21, 2022
    Assignee: CAMAS INCORPORATED
    Inventors: Jeff Fagerlund, Bradley M. Mitteness, Connie Phillips
  • Patent number: 11359194
    Abstract: The present inventors discovered that antibodies having weaker antigen-binding activity at the early endosomal pH in comparison with that at the pH of plasma are capable of binding to multiple antigen molecules with a single antibody molecule, have long half-lives in plasma, and have improved durations of time in which they can bind to antigen.
    Type: Grant
    Filed: September 14, 2020
    Date of Patent: June 14, 2022
    Assignee: Chugai Seiyaku Kabushiki Kaisha
    Inventors: Tomoyuki Igawa, Shinya Ishii, Atsuhiko Maeda, Takashi Nakai
  • Patent number: 11351257
    Abstract: This invention relates to stable formulations that can be prepared to high concentration of active agent using low amounts of detergents and to methods for producing such formulations. In particular, this invention relates to formulations containing the L19-TNF? immunocytokine.
    Type: Grant
    Filed: July 14, 2017
    Date of Patent: June 7, 2022
    Assignee: PHILOGEN S.P.A.
    Inventors: Giovanni Neri, Camilla Bacci
  • Patent number: 11352424
    Abstract: The present invention relates to antibodies that bind human T-cell immunoglobulin- and mucin-domain-containing protein-3 (Tim-3), and may be useful for treating solid and hematological tumors in combination with anti-human PD-1 antibodies, chemotherapy, and ionizing radiation.
    Type: Grant
    Filed: December 4, 2017
    Date of Patent: June 7, 2022
    Assignees: Eli Lilly and Company, Innovent Biologics (Suzhou) Co. Ltd.
    Inventors: Yiwen Li, Yi Zhang
  • Patent number: 11345722
    Abstract: Provided herein are methods for refolding denatured protein (e.g., from inclusion bodies) that do not require the use of a denaturing agent. Exemplary methods use a high pH for solubilizing denatured protein, followed by a decrease in pH for refolding the proteins.
    Type: Grant
    Filed: July 31, 2018
    Date of Patent: May 31, 2022
    Assignee: BRISTOL-MYERS SQUIBB COMPANY
    Inventors: Cristopher Hollander, Benjamin C. Blum
  • Patent number: 11339214
    Abstract: The present invention relates to a process for the purification of an antibody fragment from a periplasmic cell extract comprising a first cation exchange chromatography step and a second anion exchange chromatography step.
    Type: Grant
    Filed: January 16, 2019
    Date of Patent: May 24, 2022
    Assignee: UCB PHARMA, S.A.
    Inventors: Mariangela Spitali, Jonathan Symmons, Richard Whitcombe, Mark Robert Pearce-Higgins
  • Patent number: 11325967
    Abstract: The present invention is directed to methods of inhibiting or preventing photophobia in subjects in need thereof using anti-CGRP antibodies or antibody fragments that inhibit photophobia, especially CGRP-associated photophobia. These antibodies and fragments are useful in treating different disorders associated with photophobia such as migraine, cluster headaches and the like. The present invention also provides assays using transgenic Nestin/Ramp1 rodents, utilizing a CGRP model light aversive behavior model for identifying therapeutically effective anti-CGRP antibodies and fragments thereof having binding specificity for CGRP which inhibit or prevent photophobia in subjects in need thereof. The present invention is specifically directed to methods for identifying therapeutically effective antibodies and fragments thereof having binding specificity for CGRP that may be used to treat CGRP associated disorders such as migraine.
    Type: Grant
    Filed: April 18, 2019
    Date of Patent: May 10, 2022
    Assignees: H. LUNDBECK A/S, THE UNIVERSITY OF IOWA RESEARCH FOUNDATION
    Inventors: Andrew F. Russo, Eric A. Kaiser, Ana Recober, Adisa Kuburas, Ann C. Raddant, Brian R. Kovacevich, John Latham, Jeffrey T. L. Smith, Leon F. Garcia-Martinez